5-Dimethylaminomethylene-6,7-dihydrobenzothiophen-4(5H)-one | 209741-01-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-Dimethylaminomethylene-6,7-dihydrobenzothiophen-4(5H)-one
• 英文别名: 5-dimethylaminomethylene-6,7-dihydro-5H-benzo[b]thiophen-4-one；5-(Dimethylaminomethylene)-4-oxo-4,5,6,7-tetrahydrobenzo[b]-thiophene；5-(dimethylaminomethylidene)-6,7-dihydro-1-benzothiophen-4-one
• CAS: 209741-01-5
• 化学式: C₁₁H₁₃NOS
• 分子量: 207.296
• InChiKey: NACNWVIODNHIQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  48.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-Dimethylaminomethylene-6,7-dihydrobenzothiophen-4(5H)-one 在 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 甲苯 为溶剂， 反应 30.0h， 生成 2-oxo-2H-thieno[2,3-h](1)-benzopyran-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Synthesis of angelicin heteroanalogues: preliminary photobiological and pharmacological studies

  摘要：

  A series of angelicin heteroanalogues, in which the furan was replaced by thiophene or a 1-substituted pyrazole moiety, was synthesised in order to obtain potential therapeutic agents with antiproliferative and/or other biological activities. In general, the antiproliferative activity of the new thioangelicin, tested in different biological substrates, appeared to be higher than that of the angelicin, the natural parent compound, but lower than that of 8-MOP, the furocoumarin ordinarily used in PUVA therapy and photopheresis. Thioangelicin 6 induced strong inhibition of T2 bacteriophage infectivity and was able to significantly repress the DNA. synthesis in Ehrlich ascites cells and the clonal growth in HeLa cells. The pyrazolocoumarins did not show any noticeable effect upon UVA irradiation in all the biological systems considered. All the new angelicin heteroanalogues appeared to be free of the known phototoxicity of furocoumarins on the skin. The pyrazolocoumarins have also been tested as anti-inflammatory, analgesic, antipyretic, local anaesthetic, anti-arrhythmic and platelet antiaggregating agents by standard procedures. In this class of derivatives, 10a showed good anti-inflammatory and antipyretic properties, while 9a and 11a showed significant local anaesthetic activity. (C) 1998 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(98)00076-7
• 作为产物：
  描述：

  N,N-二甲基甲酰胺二甲基缩醛 、 6,7-Dihydro-benzo[b]thiophene-4,5-dione 反应 6.0h， 以51%的产率得到5-Dimethylaminomethylene-6,7-dihydrobenzothiophen-4(5H)-one
  参考文献：
  名称：

  Synthesis of angelicin heteroanalogues: preliminary photobiological and pharmacological studies

  摘要：

  A series of angelicin heteroanalogues, in which the furan was replaced by thiophene or a 1-substituted pyrazole moiety, was synthesised in order to obtain potential therapeutic agents with antiproliferative and/or other biological activities. In general, the antiproliferative activity of the new thioangelicin, tested in different biological substrates, appeared to be higher than that of the angelicin, the natural parent compound, but lower than that of 8-MOP, the furocoumarin ordinarily used in PUVA therapy and photopheresis. Thioangelicin 6 induced strong inhibition of T2 bacteriophage infectivity and was able to significantly repress the DNA. synthesis in Ehrlich ascites cells and the clonal growth in HeLa cells. The pyrazolocoumarins did not show any noticeable effect upon UVA irradiation in all the biological systems considered. All the new angelicin heteroanalogues appeared to be free of the known phototoxicity of furocoumarins on the skin. The pyrazolocoumarins have also been tested as anti-inflammatory, analgesic, antipyretic, local anaesthetic, anti-arrhythmic and platelet antiaggregating agents by standard procedures. In this class of derivatives, 10a showed good anti-inflammatory and antipyretic properties, while 9a and 11a showed significant local anaesthetic activity. (C) 1998 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(98)00076-7

文献信息

• Compositions useful as inhibitors of protein kinases
  申请人：Jimenez Juan-Miguel

  公开号：US20050148603A1

  公开（公告）日：2005-07-07

  The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides processes for preparing the compounds, pharmaceutically acceptable compositions comprising the compounds, and methods of using the compounds and compositions in the treatment of various disease, conditions, or disorders.

  本发明涉及作为蛋白激酶抑制剂有用的化合物。该发明还提供了制备这些化合物的方法，包括这些化合物的药用可接受组合物，以及在治疗各种疾病、症状或障碍中使用这些化合物和组合物的方法。
• Fused polycyclic 2-aminopyrimidine derivatives
  申请人：Celltech R & D Limited

  公开号：US06599908B1

  公开（公告）日：2003-07-29

  Fused polycyclic 2-aminopyrimidines of formula (1): wherein Ar is an optionally substituted aromatic or heteroaromatic group; X is a carbon or nitrogen atom; Y is a carbon or nitrogen atom; Z is a linker group; A together with X and Y forms an optionally substituted monocyclic or bicyclic aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof are described. The compounds are potent and selective inhibitors of the protein tyrosine kinases p56lck and p59fyn and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate p56lck and/or p59fyn activity is believed to have a role.

  化合物的化学式为（1）：其中，Ar为可选取代的芳香或杂芳基；X为碳或氮原子；Y为碳或氮原子；Z为连接基；A与X和Y一起形成可选取代的单环或双环芳香或杂芳基；以及其盐、溶剂化物、水合物和N-氧化物。这些化合物是蛋白酪氨酸激酶p56lck和p59fyn的有效选择性抑制剂，并可用于预防和治疗免疫疾病、高增殖性疾病和其他与不适当的p56lck和/或p59fyn活性有关的疾病。
• Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKβ inhibitors
  作者：Aimee L. Crombie、Fuk-Wah Sum、Dennis W. Powell、Darrin W. Hopper、Nancy Torres、Dan M. Berger、Yixian Zhang、Maria Gavriil、Tammy M. Sadler、Kim Arndt

  DOI：10.1016/j.bmcl.2010.04.022

  日期：2010.6

  A series of tricyclic anilinopyrimidines were synthesized and evaluated as IKK beta inhibitors. Several analogues, including tricyclic phenyl (10, 18a, 18c, 18d, and 18j) and thienyl (26 and 28) derivatives were shown to have good in vitro enzyme potency and excellent cellular activity. Pharmaceutical profiling of a select group of tricyclic compounds compared to the non-tricyclic analogues suggested that in some cases, the improved cellular activity may be due to increased clog P and permeability. (C) 2010 Elsevier Ltd. All rights reserved.